We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Understanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review.
- Authors
Begagić, Emir; Bečulić, Hakija; Džidić-Krivić, Amina; Kadić Vukas, Samra; Hadžić, Semir; Mekić-Abazović, Alma; Šegalo, Sabina; Papić, Emsel; Muchai Echengi, Emmanuel; Pugonja, Ragib; Kasapović, Tarik; Kavgić, Dalila; Nuhović, Adem; Juković-Bihorac, Fatima; Đuričić, Slaviša; Pojskić, Mirza
- Abstract
Simple Summary: This study explores hypoxia-inducible factors (HIFs) in glioblastoma development, progression, and treatment. Reviewing 104 relevant studies, it highlights diverse global contributions, with China leading at 23.1%. The most productive year was 2019, contributing 11.5% of the studies. Key factors studied included HIF1α, HIF2α, osteopontin, and cavolin-1, involving pathways such as GLUT1, GLUT3, VEGF, PI3K-Akt-mTOR, and ROS. HIF expression correlates with glioblastoma progression, survival, neovascularization, glucose metabolism, migration, and invasion. Overcoming treatment resistance and the lack of biomarkers is crucial for integrating HIF-related therapies into glioblastoma treatment to improve patient outcomes. Background: The study aims to investigate the role of hypoxia-inducible factors (HIFs) in the development, progression, and therapeutic potential of glioblastomas. Methodology: The study, following PRISMA guidelines, systematically examined hypoxia and HIFs in glioblastoma using MEDLINE (PubMed), Web of Science, and Scopus. A total of 104 relevant studies underwent data extraction. Results: Among the 104 studies, global contributions were diverse, with China leading at 23.1%. The most productive year was 2019, accounting for 11.5%. Hypoxia-inducible factor 1 alpha (HIF1α) was frequently studied, followed by hypoxia-inducible factor 2 alpha (HIF2α), osteopontin, and cavolin-1. Commonly associated factors and pathways include glucose transporter 1 (GLUT1) and glucose transporter 3 (GLUT3) receptors, vascular endothelial growth factor (VEGF), phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) pathway, and reactive oxygen species (ROS). HIF expression correlates with various glioblastoma hallmarks, including progression, survival, neovascularization, glucose metabolism, migration, and invasion. Conclusion: Overcoming challenges such as treatment resistance and the absence of biomarkers is critical for the effective integration of HIF-related therapies into the treatment of glioblastoma with the aim of optimizing patient outcomes.
- Subjects
GLIOMA treatment; VASCULAR endothelial growth factors; GLIOMAS; CARRIER proteins; CELLULAR signal transduction; SYSTEMATIC reviews; MEDLINE; REACTIVE oxygen species; ONLINE information services; HYPOXEMIA; DISEASE progression; SIGNAL peptides
- Publication
Cancers, 2024, Vol 16, Issue 11, p2089
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16112089